{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:52:09Z","timestamp":1791157929935,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shinshu University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Int"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM), yet effective pharmacological options remain limited. Imeglimin, a novel antidiabetic agent targeting mitochondrial bioenergetics, has shown potential hepatoprotective effects in preclinical studies; however, its impact on liver function and body composition in MASLD remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center pilot study analyzed prospectively collected data from 28 patients with MASLD and T2DM who were treated with imeglimin for 6 months. Clinical and biochemical parameters were assessed at baseline and at 3 and 6\u00a0months. Body composition was evaluated using bioelectrical impedance analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over 6 months, fasting blood glucose decreased from 148.5 to 131.0\u00a0mg\/dL (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015), accompanied by reductions in liver enzymes (aspartate aminotransferase: 33\u201326 U\/L,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001; alanine aminotransferase: 28.5\u201323.5 U\/L,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001). Body weight and body fat percentage also decreased (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001 and\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018, respectively), whereas no statistically significant changes were observed in skeletal muscle mass. No serious adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Imeglimin therapy was associated with favorable changes in glycemic parameters, liver enzymes, and body composition in this pilot cohort, without a statistically significant reduction in skeletal muscle mass. These findings suggest a potential metabolic and hepatic effect of imeglimin and may be particularly relevant for patients with MASLD at risk of sarcopenia. Larger prospective studies with histological or validated non-invasive endpoints are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13340-026-00931-4","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:11:23Z","timestamp":1791155483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of imeglimin on liver enzymes and body composition in patients with MASLD and type 2 diabetes: a pilot study"],"prefix":"10.1007","volume":"17","author":[{"given":"Kaede","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Iwadare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1481-1029","authenticated-orcid":false,"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-ichi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"3","key":"931_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11604-025-01930-2","volume":"44","author":"N Tamaki","year":"2026","unstructured":"Tamaki N, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatment. Jpn J Radiol. 2026;44(3):465\u201375.","journal-title":"Jpn J Radiol"},{"issue":"5","key":"931_CR2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal F, et al. Metabolic dysfunction\u2013associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79(5):1212\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"931_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97.e10.","journal-title":"Gastroenterology"},{"issue":"8","key":"931_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/hepr.14025","volume":"54","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, et al. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2024;54(8):753\u201362.","journal-title":"Hepatol Res"},{"issue":"1","key":"931_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s43856-024-00499-7","volume":"4","author":"T Iwadare","year":"2024","unstructured":"Iwadare T, et al. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease. Commun Med (Lond). 2024;4(1):73.","journal-title":"Commun Med (Lond)"},{"key":"931_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.06.044","author":"T Kimura","year":"2026","unstructured":"Kimura T, et al. IgA-enriched phenotype predicts liver-related events in MASLD. J Hepatol. 2026. https:\/\/doi.org\/10.1016\/j.jhep.2026.06.044.","journal-title":"J Hepatol"},{"issue":"1","key":"931_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/apt.18015","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60(1):61\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"931_CR8","doi-asserted-by":"crossref","unstructured":"Kimura T et al. Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol 2025.","DOI":"10.1016\/S0168-8278(25)00539-2"},{"key":"931_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70466","author":"N Tamaki","year":"2025","unstructured":"Tamaki N, et al. Gastrointestinal cancer risk in steatotic liver diseases: MASLD, MetALD and ALD. Aliment Pharmacol Ther. 2025. https:\/\/doi.org\/10.1111\/apt.70466.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"931_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"21","key":"931_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399.","journal-title":"N Engl J Med"},{"key":"931_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11010022","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, et al. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites. 2020. https:\/\/doi.org\/10.3390\/metabo11010022.","journal-title":"Metabolites"},{"issue":"12","key":"931_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"key":"931_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113.","journal-title":"Metabolism"},{"issue":"12","key":"931_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279889","volume":"17","author":"R Pan","year":"2022","unstructured":"Pan R, et al. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(12):e0279889.","journal-title":"PLoS ONE"},{"issue":"3","key":"931_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/1573399816666200705210006","volume":"17","author":"S Ida","year":"2021","unstructured":"Ida S, et al. Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus. Curr Diabetes Rev. 2021;17(3):293\u2013303.","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"931_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/dom.14277","volume":"23","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, et al. Mechanism of action of Imeglimin: a novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021;23(3):664\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"931_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40265-020-01434-5","volume":"81","author":"C Konkwo","year":"2021","unstructured":"Konkwo C, Perry RJ. Imeglimin: current development and future potential in type 2 diabetes. Drugs. 2021;81(2):185\u201390.","journal-title":"Drugs"},{"issue":"6","key":"931_CR19","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/db14-1220","volume":"64","author":"G Vial","year":"2015","unstructured":"Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015;64(6):2254\u201364.","journal-title":"Diabetes"},{"issue":"1","key":"931_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo BK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123\u201331.","journal-title":"J Hepatol"},{"issue":"3","key":"931_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, et al. Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int. 2020;11(3):165\u2013223.","journal-title":"Diabetol Int"},{"issue":"6","key":"931_CR22","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"key":"931_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102284","author":"M Komatsu","year":"2023","unstructured":"Komatsu M, et al. Citrin deficiency: clinical and nutritional features. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15102284.","journal-title":"Nutrients"},{"issue":"9","key":"931_CR24","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235\u2013481.","journal-title":"Hypertens Res"},{"issue":"8","key":"931_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5551\/jat.17152","volume":"20","author":"T Teramoto","year":"2013","unstructured":"Teramoto T, et al. Diagnostic criteria for dyslipidemia executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version. J Atheroscler Thromb. 2013;20(8):655\u201360.","journal-title":"J Atheroscler Thromb"},{"key":"931_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112806","author":"T Iwadare","year":"2022","unstructured":"Iwadare T, et al. Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10112806.","journal-title":"Biomedicines"},{"key":"931_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1329294","volume":"15","author":"T Iwadare","year":"2024","unstructured":"Iwadare T, et al. Long-term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD. Front Endocrinol (Lausanne). 2024;15:1329294.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"931_CR28","doi-asserted-by":"publisher","first-page":"1073025","DOI":"10.3389\/fmed.2023.1073025","volume":"10","author":"R Sugimoto","year":"2023","unstructured":"Sugimoto R, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne). 2023;10:1073025.","journal-title":"Front Med (Lausanne)"},{"key":"931_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100662","author":"Y Yamashita","year":"2022","unstructured":"Yamashita Y, et al. Prognostic utility of albumin-bilirubin grade in Japanese patients with primary biliary cholangitis. JHEP Rep. 2022. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100662.","journal-title":"JHEP Rep"},{"issue":"2","key":"931_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460\u20138.","journal-title":"Gastroenterology"},{"issue":"1","key":"931_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res. 2019;49(1):64\u201371.","journal-title":"Hepatol Res"},{"issue":"10019","key":"931_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390.","journal-title":"Lancet"},{"key":"931_CR33","doi-asserted-by":"publisher","first-page":"6470137","DOI":"10.1155\/2018\/6470137","volume":"2018","author":"S Kamei","year":"2018","unstructured":"Kamei S, et al. Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus. J Diabetes Res. 2018;2018:6470137.","journal-title":"J Diabetes Res"},{"issue":"1","key":"931_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) study. J Diabetes Investig. 2019;10(1):108\u201317.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"931_CR35","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/jdi.12985","volume":"10","author":"H Inoue","year":"2019","unstructured":"Inoue H, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial. J Diabetes Investig. 2019;10(4):1012\u201321.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"931_CR36","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 4","key":"931_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"931_CR38","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995\u20132040. Hepatol Int. 2021;15(2):366\u201379.","journal-title":"Hepatol Int"},{"issue":"6","key":"931_CR39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","volume":"59","author":"SI Wakabayashi","year":"2024","unstructured":"Wakabayashi SI, et al. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59(6):494\u2013503.","journal-title":"J Gastroenterol"},{"issue":"2","key":"931_CR40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00535-016-1264-3","volume":"52","author":"WK Seto","year":"2017","unstructured":"Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol. 2017;52(2):164\u201374.","journal-title":"J Gastroenterol"},{"issue":"9","key":"931_CR41","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","volume":"43","author":"X Li","year":"2024","unstructured":"Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43(9):2005\u201316.","journal-title":"Clin Nutr"},{"issue":"6","key":"931_CR42","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/hep.32578","volume":"76","author":"DH Sinn","year":"2022","unstructured":"Sinn DH, et al. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: a longitudinal cohort study. Hepatology. 2022;76(6):1746\u201354.","journal-title":"Hepatology"},{"issue":"2","key":"931_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241651","volume":"16","author":"S Hallakou-Bozec","year":"2021","unstructured":"Hallakou-Bozec S, et al. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS ONE. 2021;16(2):e0241651.","journal-title":"PLoS ONE"},{"issue":"2","key":"931_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.211","volume":"4","author":"G Vial","year":"2021","unstructured":"Vial G, et al. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab. 2021;4(2):e00211.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"9","key":"931_CR45","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/jdi.14249","volume":"15","author":"O Kikuchi","year":"2024","unstructured":"Kikuchi O, et al. Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high-fat, high-sucrose diet-fed mice. J Diabetes Investig. 2024;15(9):1177\u201390.","journal-title":"J Diabetes Investig"},{"key":"931_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16157","author":"K Fukunaga","year":"2025","unstructured":"Fukunaga K, et al. Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction\u2010associated steatotic liver disease: a multicentre study. Diabetes Obes Metab. 2025. https:\/\/doi.org\/10.1111\/dom.16157.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"931_CR47","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","volume":"37","author":"P Mofrad","year":"2003","unstructured":"Mofrad P, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286\u201392.","journal-title":"Hepatology"},{"issue":"10","key":"931_CR48","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","volume":"114","author":"S Gawrieh","year":"2019","unstructured":"Gawrieh S, et al. Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels. Am J Gastroenterol. 2019;114(10):1626\u201335.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"931_CR49","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1210\/jc.2015-1966","volume":"100","author":"P Portillo-Sanchez","year":"2015","unstructured":"Portillo-Sanchez P, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100(6):2231\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"931_CR50","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"key":"931_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111752","volume":"213","author":"H Katsuyama","year":"2024","unstructured":"Katsuyama H, et al. Real-world effectiveness of imeglimin in patients with type 2 diabetes: a retrospective longitudinal study in Japan. Diabetes Res Clin Pract. 2024;213:111752.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"931_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cgh.2016.07.031","volume":"15","author":"D Houghton","year":"2017","unstructured":"Houghton D, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2017;15(1):96-102.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"931_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13916","volume":"26","author":"O Anyiam","year":"2025","unstructured":"Anyiam O, et al. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. Obes Rev. 2025;26(7):e13916.","journal-title":"Obes Rev"},{"key":"931_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3548284","author":"M Marra","year":"2019","unstructured":"Marra M, et al. Assessment of body composition in health and disease using bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA): a critical overview. Contrast Media Mol Imaging. 2019. https:\/\/doi.org\/10.1155\/2019\/3548284.","journal-title":"Contrast Media Mol Imaging"}],"container-title":["Diabetology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13340-026-00931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13340-026-00931-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13340-026-00931-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:11:24Z","timestamp":1791155484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13340-026-00931-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s13340-026-00931-4","relation":{},"ISSN":["2190-1678","2190-1686"],"issn-type":[{"value":"2190-1678","type":"print"},{"value":"2190-1686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kaede Fujita declares no conflict of interest; Takanobu Iwadare declares no conflict of interest; Takefumi Kimura declares no conflict of interest; Yuma Kamijo declares no conflict of interest; Taiki Okumura declares no conflict of interest; Shun-ichi Wakabayashi declares no conflict of interest; Hiroyuki Kobayashi declares no conflict of interest; Tomoo Yamazaki declares no conflict of interest; Naoki Tanaka declares no conflict of interest; Hideo Kunimoto declares no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Committee for Medical Ethics of Nagano Municipal Hospital (ID number: 0059). The requirement for written informed consent was waived by the committee because this was a retrospective analysis using anonymized information.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}